Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors.
Klein M, Watson D, Castro M, Kapoor S, Nair PR, Rajagopalan S, Qin H, Glaser M, Westanmo A, Lala DA, Kumar A, Chauhan J, G P, Ullal YS, Kulkarni S, Narvekar Y, Ghosh A, Tyagi A, Patil M, Macpherson MD, Wingrove JA, Patil T, Aggarwal C, Ganti AK. Use of an Integrative Genomics Approach to Identify Metastatic NSCLC Patients Benefiting From the Addition of Chemotherapy to Immune Checkpoint Inhibitors. Clin Lung Cancer. 2026 May; 27(4):5-13.